BENEFICIARIES
REMOD-HEALING gathers 14 academic and industrial partners across 8 countries in Europe and Latin America.
Together, these partners bring complementary expertise in wound healing, extracellular matrix biology, proteolysis, and translational medicine. The consortium combines excellence in research, technology, and training to address the global challenges of wound healing and regenerative medicine.
CONNECTING EXCELLENCE ACROSS DISCIPLINES TO TRANSFORM WOUND-HEALING RESEARCH
BENEFICIARY
The Centre National de la Recherche Scientifique is a multidisciplinary public institution under the responsibility of the French Ministry of Higher Education and Research. CNRS carries out research in all scientific fields of knowledge and has a long history of interdisciplinary programs. It is the largest governmental research organization in France (32,000 employees; 1,100 research units) and the largest fundamental science agency in Europe. The Tissue Biology and Therapeutic Engineering Laboratory (LBTI) (https://lbti.ibcp.fr/) is one of the research units managed by CNRS, in collaboration with the associated partner Université Claude Bernard Lyon I (UCBL). It is a leading French research laboratory with around 120 employees, specializing in the study of healthy and diseased tissues, e.g. skin, and in the development of innovative therapeutic strategies with high potential for translation toward industrial and clinical applications.
BENEFICIARY
The University of Costa Rica (UCR) is the largest in the country, with a student population of 40,000 in graduate and undergraduate programs. It encompasses schools in all fields of knowledge, including basic natural sciences, health sciences, social sciences, engineering, agricultural sciences, and humanities. The Instituto Clodomiro Picado (ICP, http://www.icp.ucr.ac.cr/) is a Research Institute of the University of Costa Rica with a long history of research in snake venoms and antivenoms and is recognized as a reference centre on these topics. It participates in training graduate and undergraduate students of UCR and other universities. The Institute has significantly contributed to increasing the knowledge in snake venom toxinology, evidenced in more than 600 publications in international journals and book chapters, through collaborations with different institutions worldwide.
BENEFICIARY
The Medical Center – University of Freiburg is among the largest UMC in Germany, with around 15.000 employees, including 1.900 doctors and 4.400 nurses and carers who provide healthcare services to more than 90.000 inpatients, and 900.000 outpatients every year. It engages in research, teaching and healthcare as its core responsibilities, always with the goal of offering current and future patients treatment informed by the latest scientific findings. It collaborates closely with the Faculty of Medicine, which is one of the most prestigious research-driven medical schools in Germany. Over 110 professors and 2500 academic staff are committed to excellence in research and teaching for more than 3500 students. The Ranking based on third party funding from the DFG for life sciences places Freiburg within the top-three German universities.
BENEFICIARY
The Technical University of Denmark (DTU) is an international elite university that develops technology for people. DTU has 12,900 students and 6,000 employees, working in an international atmosphere and an inclusive, evolving, and informal working environment. DTU has campuses in all parts of Denmark and in Greenland and collaborates with the best universities around the world. The Department of Biotechnology and Biomedicine trains students of biotechnology and human life science engineering in biochemistry, biotechnology, synthetic biology, fermentation, protein science, and biotherapeutics and is integrated into their M.Sc.Eng. education with other institutes (anatomy, physiology) of the DTU. The institute is renowned for the research works on protein science, proteomics, antibody discovery, toxinology, mycology, microbiology, and immunology. The Section for Medical Biotechnology is part of the Department of Biotechnology and Biomedicine at the DTU. Research in the section is focused on host-environment interactions using a range of system-wide approaches. These are supported by a state-of-the-art proteomics facility with special expertise in protease proteomics, extracellular matrix analysis and degradomics.
BENEFICIARY
The Paris-Lodron-University of Salzburg (PLUS) comprises six faculties and trains more than 18,000 students in more than 100 Bachelor & Master study programs. Research and teaching are at the heart of PLUS. With more than 2,000 staff, PLUS participated in 36 H2020 projects, including 7 ERC projects and 11 Marie Skłodowska Curie Actions. The laboratory of Chemical and Structural Biology at the Department of Biosciences at the Natural and Life Sciences faculty of PLUS contributes to the training of students in molecular biology and medical biology at the bachelor, master and PhD level. The focus of the laboratory is the elucidation of structure and function of proteases, including their mechanisms of activation, activity regulation and inhibition.
BENEFICIARY
The University of Manchester (UNIMAN) is one of the world’s top 30 universities and has an annual income of more than £1billion (€1.12billion). UNIMAN attracts the highest calibre researchers and teachers with 25 Nobel Prize winners among our current and former staff and students. Research is at the heart of the University, with over 2,000 staff active in research. UNIMAN participated in 360 H2020 projects including 102 ERC projects, 73 Marie Sklodowska Curie Fellowships and 34 Initial Training Networks across the Faculties of Humanities/ Biology, Medicine and Health/ Science and Engineering.
BENEFICIARY
With more than 45,000 students, the University of Münster (UM) is one of the largest universities in Germany with 15 faculties, an extensive range of degree programs (more than 7.600 graduations p.a.) and multifaceted research profile (e.g. 2 Excellence Clusters, 12 Collaborative Research Centers (CRCs), 6 Transregio-CRCs, 24 Priority Programs). At the Faculty of Medicine, more than 2,000 researchers in 80 different institutes, clinics and centers, and in 2 Clinical Research Units combine their efforts to study diseases, explore biomedical principles, and develop novel tools for diagnosis and treatment, and to integrate them into an innovative research and teaching environment. Almost 3,300 enrolled students receive in-depth scientific and clinical training. The Medical Faculty forms a cooperative functional unit with the University Hospital Münster (UKM). The hospital supports the faculty’s research and teaching and is responsible for patient care, which enables scientists to actively combine clinical research with strong interdisciplinary basic research. The Institute of Physiological Chemistry and Pathobiochemistry (IPCP) trains students of medicine and dentistry in biochemistry. It is known for its research on extracellular matrix, integrins, endothelial and cancer cells. Different novel snake venom components were identified here as integrin inhibitors, platelet activators or agonists of novel targets (e.g.neuropilin-1).
BENEFICIARY
The University of Liège comprises 11 faculties located in 4 campuses. It trains more than 29,000 students in more than 240 Bachelor and Master study programs, and has 6000 employees. It has cooperation and exchange agreements with 673 partner institutions from 71 countries.
The Centre for Protein Engineering (CIP) is a multidisciplinary research Centre. It is part of the Faculty of Sciences and of the Research Unit InBioS (Integrative Biological Sciences). The Centre provides complementary approaches for the analysis of structure and function relationships of proteins. Ten closely interacting research teams constitute the framework of the Centre offering cutting-edge expertise, from isolated proteins to integrated cellular networks.
BENEFICIARY
Politechnika Wrocławska (PWR) is one of the leading technical universities in Poland. PWR scientists carry out their research in fourteen faculties within four fields: engineering and technology, natural sciences, medical sciences, social sciences. There are currently 22 949 students, 154 doctoral students and 747 people at the Doctoral School pursuing their degree programmes under the supervision of over 2 280 academic teachers at PWR’s 14 faculties and three branches. The faculty members of PWR participated among others in several programs funded by Europe. In June 2016, the European Commission granted PWR the logo Human Resources&Excellence. In 2022, PWR joined the UNITE! Network, the European Universities alliance of innovation, technology and engineering.
BENEFICIARY
The Dutch SME MIMETAS, founded in 2013 in Leiden, is today’s world market leader in the emerging field of Organ-on-a-Chip technology. MIMETAS develops microfluidic Organ-on-a-Chip models to specification in OrganoPlate, markets OrganoPlate and performs self-funded R&D on ground-breaking Organ-on-a-Chip models. Their unique microfluidic platform enables testing of compounds in high throughput on miniaturized 3D organ models. These models offer better predictivity as compared to laboratory animal testing and conventional cell culture models. The MIMETAS OrganoPlate® platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation, thus mimicking important aspects of tissues and organs. MIMETAS has locations in Oegstgeest and Enschede, the Netherlands, Gaithersburg, Maryland, US, and Tokyo, Japan. MIMETAS counts the majority of the top-50 pharmaceutical companies as its customers, as well as some leading consumer goods, and chemical companies. The company is run by an experienced management team supported by a seasoned board, and currently employs over 115 professionals. The company already generates year-on year multi-million revenues (2020: €3.1M) and envisions to grow to a profitable company by 2025, with over 100mn€ revenues and over 275 employees worldwide. In 2018 it has closed a 20.5mn$ investment round to further consolidate its market leader position.
BENEFICIARY
Nordic Bioscience specializes in advancing novel biomarkers for fibroinflammatory diseases through development, validation, and evaluation. Engaged in over 25 academic collaborations in fibrosis, allergy, and dermatology, the company contributes to drug development across preclinical to phase IV studies by providing pharmacodynamic and mode of action markers. Over two decades, Nordic Bioscience has pioneered biomarkers targeting immune-cell activity, exemplified by CTX-I in 2003, which detects type I collagen cleaved by Cathepsin K, indicative of bone turnover. Since 2012, the company has introduced PRO-C3 and PRO-C6, biomarkers for fibroblast activity, supported by FDA acknowledgement, along with C4G for T-cell activity and CPa9-HNE for neutrophil activity, with forthcoming FDA support anticipated in 2024. Based on a strong translational capability, assay development expertise, and the previous success with 510K approvals for in vitro diagnostic use by the FDA, it is expected to commercialize the discoveries of this project, by expanding the biomarkers to a new indication, test the biomarkers in novel pre-clinical models, and develop new biomarkers. In addition, the goal is to broaden the intellectual property (IP).
ASSOCIATED PARTNER
Université Claude Bernard Lyon I (UCBL) is the fifth largest French university with more than 46,000 students and 4,600 employees. It is organized in 13 departments covering the fields of science and technology, health and sport. It hosts 47 masters and 12 doctoral schools. UCBL is also one of the managing bodies of the research institute of PI-1 (LBTI) together with CNRS.
ASSOCIATED PARTNER
The Albert-Ludwigs-Universität Freiburg is one of the oldest German universities and one of the nation’s leading research and teaching institutions (ca. 25,000 students from more than 100 nations). It actively fosters interdisciplinary research and offers cutting edge research facilities and world class science in all academic fields. The university actively promotes international exchange facilitated by its central location in Europe. The university has formally endorsed the guidelines of the European Charter for Researchers and the Code of Conduct in 2007.
ASSOCIATED PARTNER
University of Leiden has seven faculties and a campus in both Leiden and The Hague, around 34,000 students and 7,600 staff. DC-10 at Mimetas will be enrolled in Leiden University Graduate Program and will be supervised for PhD by Prof. Dr Thomas Hankemeier, in the Leiden Academic Centre for Drug Research (LACDR) research institute. The LACDR is a member of the ULLA, the European University Consortium for Pharmaceutical Sciences. The ambition of the LACDR is to develop innovative analytical strategies for metabolomics-driven health monitoring and systems biology studies.
MEET THE SCIENTISTS LEADING REMOD-HEALING’S RESEARCH AND TRAINING